Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery

  • ACS Omega. 2024 Jun 13;9(25):26762-26779. doi: 10.1021/acsomega.4c00617.
Nilofer Bano  1  2 Sana Parveen  1  3 Mohd Saeed  4 Samra Siddiqui  5 Mohammad Abohassan  6 Snober S Mir  1  3
Affiliations
  • 1. Molecular Cell Biology Laboratory, Integral Centre of Excellence for Interdisciplinary Research (ICEIR-4), Integral University, Kursi Road, Lucknow 226026, India.
  • 2. Department of Bioengineering, Faculty of Engineering, Integral University, Kursi Road, Lucknow 226026, India.
  • 3. Department of Biosciences, Faculty of Science, Integral University, Kursi Road, Lucknow 226026, India.
  • 4. Department of Biology, College of Sciences, University of Hail, P.O. Box 2240, Hail 55476, Saudi Arabia.
  • 5. Department of Health Services Management, College of Public Health and Health Informatics, University of Hail, Hail 55476, Saudi Arabia.
  • 6. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 61421, Saudi Arabia.
Abstract

Drug repurposing is a method of investigating new therapeutic applications for previously approved medications. This repurposing approach to "old" medications is now highly efficient, simple to arrange, and cost-effective and poses little risk of failure in treating a variety of disorders, including Cancer. Drug repurposing for Cancer therapy is currently a key topic of study. It is a way of exploring recent therapeutic applications for already-existing drugs. Theoretically, the repurposing strategy has various advantages over the recognized challenges of creating new molecular entities, including being faster, safer, easier, and less expensive. In the real world, several medications have been repurposed, including aspirin, metformin, and chloroquine. However, doctors and scientists address numerous challenges when repurposing drugs, such as the fact that most drugs are not cost-effective and are resistant to bacteria. So the goal of this review is to gather information regarding repurposing pharmaceuticals to make them more cost-effective and harder for bacteria to resist. Cancer patients are more susceptible to Bacterial infections. Due to their weak immune systems, Antibiotics help protect them from a variety of infectious diseases. Although Antibiotics are not immune boosters, they do benefit the defense system by killing bacteria and slowing the growth of Cancer cells. Their use also increases the therapeutic efficacy and helps avoid recurrence. Of late, Antibiotics have been repurposed as potent Anticancer agents because of the evolutionary relationship between the prokaryotic genome and mitochondrial DNA of eukaryotes. Anticancer Antibiotics that prevent Cancer cells from growing by interfering with their DNA and blocking growth of promoters, which include anthracyclines, daunorubicin, epirubicin, mitoxantrone, doxorubicin, and idarubicin, are another type of FDA-approved Antibiotics used to treat Cancer. According to the endosymbiotic hypothesis, prokaryotes and eukaryotes are thought to have an evolutionary relationship. Hence, in this study, we are trying to explore Antibiotics that are necessary for treating diseases, including Cancer, helping people reduce deaths associated with various infections, and substantially extending people's life expectancy and quality of life.

Products